Free Trial
NASDAQ:ICCC

ImmuCell (ICCC) Stock Price, News & Analysis

ImmuCell logo
$6.25 0.00 (0.00%)
Closing price 05/28/2025 03:59 PM Eastern
Extended Trading
$6.25 0.00 (0.00%)
As of 05/28/2025 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About ImmuCell Stock (NASDAQ:ICCC)

Key Stats

Today's Range
$6.23
$6.31
50-Day Range
$4.78
$6.52
52-Week Range
$3.34
$6.84
Volume
13,885 shs
Average Volume
21,999 shs
Market Capitalization
$56.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

ImmuCell Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
4th Percentile Overall Score

ICCC MarketRank™: 

ImmuCell scored higher than 4% of companies evaluated by MarketBeat, and ranked 917th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for ImmuCell.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of ImmuCell is -12.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of ImmuCell is -12.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    ImmuCell has a P/B Ratio of 1.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about ImmuCell's valuation and earnings.
  • Percentage of Shares Shorted

    0.20% of the float of ImmuCell has been sold short.
  • Short Interest Ratio / Days to Cover

    ImmuCell has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in ImmuCell has recently increased by 82.81%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    ImmuCell does not currently pay a dividend.

  • Dividend Growth

    ImmuCell does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.20% of the float of ImmuCell has been sold short.
  • Short Interest Ratio / Days to Cover

    ImmuCell has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in ImmuCell has recently increased by 82.81%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    ImmuCell has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for ImmuCell this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, ImmuCell insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.60% of the stock of ImmuCell is held by insiders.

  • Percentage Held by Institutions

    Only 13.47% of the stock of ImmuCell is held by institutions.

  • Read more about ImmuCell's insider trading history.
Receive ICCC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmuCell and its competitors with MarketBeat's FREE daily newsletter.

ICCC Stock News Headlines

Is President Trump Lying To You With This?
President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to protect your 401(k), IRA, or pension from market chaos and currency collapse? The 2025 Wealth Protection Guide reveals a legal IRS strategy that may let you keep more of your retirement—regardless of what happens next. Trump’s warning was real. So is this opportunity.
See More Headlines

ICCC Stock Analysis - Frequently Asked Questions

ImmuCell's stock was trading at $5.15 at the beginning of 2025. Since then, ICCC shares have increased by 21.4% and is now trading at $6.25.
View the best growth stocks for 2025 here
.

ImmuCell Co. (NASDAQ:ICCC) released its quarterly earnings results on Wednesday, May, 14th. The biotechnology company reported $0.16 earnings per share for the quarter. The biotechnology company earned $8.07 million during the quarter. ImmuCell had a negative net margin of 15.99% and a negative trailing twelve-month return on equity of 15.32%.
Read the conference call transcript
.

Top institutional shareholders of ImmuCell include Mesirow Financial Investment Management Inc. (0.14%).
View institutional ownership trends
.

Shares of ICCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that ImmuCell investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Altimmune (ALT), Biocept (BIOC), ImmunoGen (IMGN), Novavax (NVAX) and Pfizer (PFE).

Company Calendar

Last Earnings
5/14/2025
Today
5/28/2025
Next Earnings (Estimated)
8/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Diagnostic substances
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ICCC
Employees
70
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$5.78 million
Pretax Margin
-15.96%

Debt

Sales & Book Value

Annual Sales
$27.30 million
Price / Cash Flow
N/A
Book Value
$3.23 per share
Price / Book
1.93

Miscellaneous

Free Float
8,324,000
Market Cap
$56.48 million
Optionable
Not Optionable
Beta
0.23

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NASDAQ:ICCC) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners